The worldwide license agreement builds upon AbbVie’s commitment to pursue transformational disease-modifying therapies in AD.
Tau stabilizes proteins that are responsible for the structure and transport in neuronal cells and abnormal accumulation of altered tau protein is a major indicator in a variety of neurodegenerative conditions such as AD, Progressive Supranuclear Palsy and Corticobasal Degeneration.
In these neurodegenerative conditions, the development of tau pathology correlates with clinical disease progression.
AbbVie pharmaceutical discovery vice-president Jim Sullivan said: "C2N’s portfolio of anti-tau antibodies represents one of the most promising approaches to delaying progression of devastating neurodegenerative disease.
"Combining the world class expertise in Alzheimer’s disease at C2N with AbbVie’s proven capabilities in neuroscience will enable the rapid advancement of anti-tau antibodies into patients."
Both the companies have not disclosed the financial terms of the collaboration.
AbbVie is focused on the development and marketing of advanced therapies that address some of the world’s most complex and serious diseases.
C2N Diagnostics is commercializing a suite of biomarker assays and tools to allow drug discovery, clinical drug development at lower risk and cost as well as for the early detection of debilitating neurodegenerative disorders.